FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
This article was originally published in The Tan Sheet
Executive Summary
FDA's Botanical Review Team on Oct. 31 approved its first botanical drug, MediGene's Polyphenon E ointment
You may also be interested in...
Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path
Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.
Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path
Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.
Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path
Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.